Cervical Cancer Serum
Powered by BiozAbout:Cervical Cancer Serum from consented donors with confirmed cervical cancer, processed and frozen within 24 hours of collection. Supports tumour marker research (SCC-Ag, CEA, CA 125), HPV E6 and E7 antibody assay development, soluble checkpoint and cytokine profiling, and tumour immunology biomarker discovery. Donors can be stratified by histology, FIGO stage, HPV genotype and treatment status, with matched healthy controls available.
About Cervical Cancer Serum
Cervical Cancer Serum for Tumour Immunology and Oncology Biomarker Research
Our Cervical Cancer Serum is sourced from IRB-consented donors clinically diagnosed with cervical cancer. Each sample is processed and frozen within 24 hours of collection to ensure consistency and high quality for tumour immunology, biomarker and translational oncology studies. Cervical cancer is a neoplastic disease; the overwhelming majority of cases arise from persistent infection with high-risk human papillomavirus, which makes it one of the few solid tumours with a defined viral aetiology.
Why Serum for Cervical Cancer Research
- Nearly all cervical cancers are driven by persistent high-risk HPV, most commonly types 16 and 18. The viral E6 and E7 oncoproteins inactivate p53 and Rb respectively, and antibody responses to E6 and E7 are detectable in serum in a substantial fraction of HPV-driven cancers, unlike in transient infection.
- Squamous cell carcinoma antigen (SCC-Ag) is the tumour marker most established in squamous cervical carcinoma and is measured in serum; CEA and CA 125 are more relevant to adenocarcinoma histology.
- Cervical tumours are typically immune-infiltrated and PD-L1 expressing, and checkpoint blockade is part of the treatment landscape for recurrent and metastatic disease. Serum supports profiling of soluble immune checkpoint molecules, chemokines and inflammatory cytokines that reflect that tumour immune contexture.
- Serum, having had fibrinogen and most clotting factors removed, is the matrix on which most commercial tumour marker and serology immunoassays are validated, which matters when benchmarking a new assay against an established one.
- Serum captures the systemic host response to tumour burden, including acute-phase reactants and nutritional or metabolic indices that inform prognostic modelling alongside FIGO stage.
- Circulating HPV tumour DNA is an active area of research, but cell-free DNA work is generally better served by plasma; matched cervical cancer plasma from the same donors can be requested for that purpose.
Donor Stratification Available
- Histology: squamous cell carcinoma, adenocarcinoma, or adenosquamous
- FIGO stage and grade, and localised versus recurrent or metastatic disease
- HPV status and genotype where documented, including HPV 16 and 18
- Treatment status: treatment-naive, post-surgical, chemoradiation, platinum-based chemotherapy, anti-VEGF therapy, or immune checkpoint inhibitor
- Prior cervical screening and cytology or colposcopy history, and HIV co-infection status where documented
- Matched healthy controls available, as well as HPV-positive donors without malignancy for comparison
Product Features
- Collected from clinically confirmed cervical cancer donors
- Research Use Only (RUO)
- Processed and frozen within 24 hours of collection
- IRB-approved protocols with documented consent
- Standard and custom aliquot volumes; volumes reported per lot
- Matched plasma, whole blood and PBMC from the same donors available on request
De-identified Donor Data
- Diagnosis confirmation
- Age, sex assigned at birth, and ethnicity
- Donor-reported medical history and comorbidities
- Stage, histology and treatment details available on request
Applications
- Tumour marker research, including SCC-Ag, CEA and CA 125
- HPV E6 and E7 antibody assay development and seroepidemiology
- Serum cytokine, chemokine and soluble checkpoint molecule profiling
- Tumour immunology and immune contexture biomarker discovery
- Prognostic and treatment-response biomarker validation
- Serum proteomics, glycoproteomics and metabolomics
- Therapeutic candidate screening and target validation
- Disease-state control matrix for oncology immunoassay qualification
Other Cervical Cancer Specimen Types
- Cervical Cancer Plasma
- Cervical Cancer Whole Blood
- Cervical Cancer PBMC
- Human Papillomavirus (HPV) Serum
- Human Papillomavirus (HPV) Plasma
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Cervical cancer serum is available in standard and custom volumes. For pricing, current availability, or a quote on a stratified donor cohort, email learnmore@sanguinebio.com. For international orders or documentation requirements, please contact us to ensure compatibility with your country’s regulations. To browse other disease states in this specimen type, visit our human serum page.
Applications
- Immunology and translational research
- Biomarker discovery and validation
- Drug screening and assay development
- Vaccine and infectious disease research
Product Features
- Research Use Only (RUO), Serum
- Sourced from screened, consented donors
- Processed under validated SOPs
- QC tested for purity, viability, and sterility
- Processed within 24 hours of collection
- IRB-approved protocols with electronic informed consent
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human Serum are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Download
Serum Isolation
Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Serum
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Pair with a Healthy Control
Match your Cervical Cancer Serum with normal donor samples for comparison
Healthy Serum
102 In Stock View InventoryNeed a custom Serum cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.